NCT03711825View on ClinicalTrials.gov

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

October 1, 2018

Study Completion Date

November 13, 2018

Conditions
Alzheimer DiseaseGastric RetentionHealthy
Interventions
DRUG

LYN-057

Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)

PROCEDURE

Imaging Assessment (MRI)

Imaging assessments \[MRI\] will be performed on specified days according to protocol

PROCEDURE

Imaging Assessment (U/S)

Imaging assessments (abdominal U/S) will be performed on specified days according to protocol

Trial Locations (1)

5000

CMAX, Adelaide

All Listed Sponsors
lead

Lyndra Inc.

INDUSTRY

NCT03711825 - Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults | Biotech Hunter | Biotech Hunter